Skip to main content
. 2021 Nov;20(11):895–906. doi: 10.1016/S1474-4422(21)00263-5

Table 3.

Main primary analysis according to treatment group and MRI scan modality

Baseline
12-month follow-up
n Brain volume, mL BSI n Brain volume*, mL BSI
1·5 T
Losartan group 22 1021 (100) .. 15 987 (84) 20·9 (10·8)
Placebo group 22 1051 (103) .. 17 1033 (109) 21·9 (11·6)
3 T
Losartan group 83 1023 (100) .. 69 1005 (102) 19·8 (10·8)
Placebo group 84 1032 (114) .. 70 1015 (114) 18·4 (9·9)

Data are n or mean (SD). Repeat of main primary analysis including treatment group by scan modality (1·5 T vs 3 T) interaction term. BSI=boundary shift interval.

*

p=0·93.

p=0·73